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Abstract
The primary focus of this investigation was to study
the relationship between neuroendocrine (NE) differ-
entiation and epidermal growth factor (EGF) because
both have been implicated in the progression of pros-
tate cancer. For this purpose, we used gefitinib and
trastuzumab,which are inhibitors of EGF receptor (EGFR)
and ErbB2, respectively. EGF prevents NE differentiation
induced by androgen depletion. This effect is prevented
by gefitinib, which blocks the activation of EGFR and
ErbB2, stimulation of mitogen-activated protein kinase
(MAPK), and cell proliferation induced by EGF. Con-
versely, trastuzumab does not inhibit the effect of EGF
on EGFR phosphorylation, MAPK activity, cell prolifer-
ation, and NE differentiation, although it reduces ErbB2
levels specifically, suggesting that ErbB2 is not neces-
sary to inhibit NE differentiation. Prevention of NE dif-
ferentiation by EGF is mediated by a MAPK-dependent
mechanism and requires constitutive Akt activation. The
abrogation of the PI3K/Akt pathway changes the role of
EGF from inhibitor to inductor of NE differentiation. We
show that EGFR tyrosine kinase, MAPK, and PI3K in-
hibitors inhibit the cell proliferation stimulated by EGF
but induce the acquisition of NE phenotype. Altogether,
the present data should be borne in mind when de-
signing new clinical schedules for the treatment of
prostate cancer, including the use of ErbB receptors
and associated signaling pathway inhibitors.
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Introduction
Prostate cancer is one of the most common malignancies
among men in the western world and a major health prob-
lem in many industrialized countries. Because the tumor is
initially androgen-dependent in the majority of cases, endo-
crine manipulation is the first-line therapy for metastatic and
locally advanced cancers and often leads to remission or
stabilization of the disease [1]. However, this period of re-
mission is invariably followed by tumor relapse, and avail-
able treatment options are only palliative. Patients with
metastatic prostate cancer develop an androgen-refractory
phenotype that leads to disease progression and eventual death
[2]. Therefore, an understanding of what drives progression to
androgen independence is critical. In fact, the prostate is known
to be dependent not exclusively on androgens but also on
growth factors and neuropeptides secreted by neuroendocrine
(NE) cells that maintain normal prostate function and play a role
in the development of pathological conditions [3].
NE cells comprise a minor fraction of the total epithelial pop-
ulation but are thought to have a paracrine role in the growth
and differentiation of a normal prostate gland [4]. These cells
secrete a number of neuropeptides from a large class that
includes bombesin, neurotensin, serotonin, calcitonin, thyroid-
stimulating hormone, and parathyroid hormone–related pep-
tide, which exhibit a wide range of cellular activities associated
with tumor proliferation, transformation, and metastasis [4].
These cells lack nuclear androgen receptors [5] and, thus, rep-
resent an androgen-insensitive cell phenotype in the prostate.
Long-term androgen ablation therapy tends to select pros-
tate tumor populations that are enriched in NE cells [6,7].
Those tumors with an increased NE cell population are often
more aggressive and have a poorer prognosis [4,8–10]. There-
fore, it has been hypothesized that NE cells can lead to the de-
velopment and growth of androgen-refractory prostate tumors
through the secretion of neuropeptides that induce the prolif-
eration of adjacent carcinoma cells in an androgen-depleted
condition [11]. This notion is supported by the observation that
the proliferation index of proximate cancer cells surrounding
NE cells is higher than that of distal cancer cells [12,13].
However, the exact role that NE cells play in the development
of androgen-independent prostate carcinomas is a matter of
debate, and the molecular mechanism of NE cell enrichment
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remains an enigma [14]. Some authors have found that the
acquisition of these NE characteristics is fully reversible, sug-
gesting that the phenotype of cells within tumors is dynamic
and will be determined, in part, by the balance of differenti-
ating and mitogenic factors in the local environment.
One of the most important mitogenic factors presently
known to regulate normal prostate function is epidermal growth
factor (EGF) [15,16]. Our current knowledge on the role of EGF
strongly suggests that this growth factor plays a fundamental
role in stromal–epithelial interactions during the initiation and
progression of prostate cancer. In primary tumors, neoplastic
cells express EGF receptor (EGFR), and surrounding stro-
mal cells express transforming growth factor-a, whereas in
advanced disease, neoplastic cells coexpress both EGFR and
transforming growth factor-a [17]. However, EGF can stimulate
androgen-mediated gene transcription in the absence of an-
drogen, suggesting that the androgen signaling pathway may
be activated by an androgen-independent mechanism [18].
EGF binds specifically to ErbB1 or EGFR, the prototypical
member of the ErbB family of receptors that includes ErbB2
(HER2, neu), ErbB3 (HER3), and ErbB4 (HER4) [19–21].
Ligand binding to a cognate ErbB receptor induces receptor
homodimer and heterodimer formation, leading to stimula-
tion of the intrinsic tyrosine kinase activity of the receptor.
These activated receptor tyrosine kinase complexes acti-
vate, in turn, a number of cytoplasmic signaling pathways, in-
cluding the mitogen-activated protein kinase (MAPK) and
phosphoinositol 3V-kinase (PI3K)/Akt pathways. Although no
direct ligand for ErbB2 has been identified, it appears to be
the preferred heterodimerization partner of all ErbB proteins
and plays an important role in the potentiation of ErbB re-
ceptor signaling. In particular, EGFR and ErbB2 are impor-
tant regulatory elements of the growth and progression of
many epithelial-derived tumors, including prostate cancer [16].
The primary focus of this investigation was to study the
relationship between NE differentiation and EGF because
both have been implicated in the progression of prostate cancer.
In this report, we present evidence that EGF prevents NE
differentiation induced by androgen depletion. This effect
does not require the presence of ErbB2 and occurs through
the action of an extracellular signal–regulated kinase (ERK)
1/2–dependent mechanism. Furthermore, our results suggest
that the constitutive activation of Akt detected in these cells
supports this effect of EGF because abrogation of PI3K/Akt
signaling changes the EGF-induced NE differentiation–inhib-
itory response toward cell cycle arrest and NE differentiation.
Materials and Methods
Cell Culture
LNCaP human prostate cancer cells were obtained from
the American Type Culture Collection (Manassas, VA) and
were routinely cultured in RPMI 1640 medium (Invitrogen,
San Diego, CA) containing 7% fetal bovine serum (FBS; In-
vitrogen), 0.25 mg/ml penicillin, 0.25 mg/ml streptomycin,
and 2.5 mg/ml fungizone. Cells were maintained at 37jC in a
humidified atmosphere of 95% air and 5% CO2.
Reagents
EGF was purchased from Sigma (St. Louis, MO), U0126
was purchased from Promega (Madison, WI), LY294002 was
purchased from Calbiochem (Darmstadt, Germany), gefitinib
was provided by Astra-Zeneca (Alderly Park, Cheshire, UK),
and trastuzumab was obtained from Roche Farma (Madrid,
Spain). The corresponding antibodies used for these analyses
included the following: anti–phospho-ErbB2 (clone PN2A),
anti-ErbB2 (clone 3B5), and anti-neurone-specific enolase
(NSE) from Lab Vision Corporation Neomarkers (Fremont,
CA); anti–phospho-EGFR (Y1068), anti–phospho-Akt, and
anti–phospho-p44/42 MAPK (Thr202/Tyr204) from Cell Sig-
naling Technology, Inc. (Denvers, MA); anti-EGFR from BD
Transduction Laboratories (San Diego, CA); and anti-actin
from Calbiochem.
Western Blot Analysis
Cells were treated as indicated in figure legends. They
were then collected, washed twice in cold phosphate-buffered
saline (PBS), and solubilized with 50 mM Tris–HCl buffer
(pH 7.5) containing 140 mM NaCl, 1 mM EDTA, 0.3 mg/ml
soybean trypsin inhibitor, and 0.1 mM phenylmethylsulfonyl
fluoride (buffer A) in the presence of 1% Triton X-100 and
0.5 mM sodium orthovanadate. The mixture was gently agi-
tated for 30 minutes at 4jC and then centrifuged at 18,500g
for 20 minutes. Soluble proteins (50–90 mg) were resolved
through 7.5% sodium dodecyl sulfate polyacrylamide gels,
transferred to a nitrocellulose membrane, and immunoblotted
with primary antibodies. Immunoreactive proteins were visu-
alized by the ECL immunodetection system (Pierce, Rockford,
IL) with horseradish peroxidase–conjugated secondary anti-
bodies and quantified using the Image Scion computer pro-
gram Scion Corporation (Frederick, MD).
Immunoprecipitation
Cells were washed and solubilized with 50 mM Tris–HCl
buffer (pH 7.5) containing 140 mMNaCl, 1 mMEDTA, 0.3 mg/
ml soybean trypsin inhibitor, and 0.1 mM phenylmethylsulfo-
nyl fluoride (buffer A) in the presence of 1% Triton X-100 and
0.5 mM sodium orthovanadate. The mixture was gently agi-
tated for 30 minutes at 4jC and thereafter centrifuged at
18,500g for 20 minutes. Soluble proteins (400–600 mg) were
incubated for 2 hours at 4jC with an anti–EGFR protein anti-
body (Santa Cruz Biotechnology, Santa Cruz, CA). Protein
G-Sepharose (Sigma, St. Louis, MO) was then added, and
samples were rotated for another hour. Immunoprecipitates
were then washed thrice with buffer A and resuspended in
Laemmli sample buffer. The samples were subjected to so-
dium dodecyl sulfate–polyacrylamide gel electrophoresis and
electrophoretically transferred to a nitrocellulose membrane.
Western blot analyses were performed as described above.
Flow Cytometric Analysis of ErbB2 Localization
The amount of ErbB2 at the cell surface was determined
by flow cytometry using indirect fluorescent staining meth-
ods. Briefly, cells were plated onto 60-mm culture plates.
After 48 hours, cells were starved in serum-free medium for
24 hours and subsequently treated with trastuzumab. After
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24 hours, the cells were harvested with trypsin and EDTA,
and then washed with PBS containing 1% bovine serum
albumin (PBS-A). In the primary reaction, the cells were in-
cubated at 4jC for 30 minutes with 5 mg/ml trastuzumab or
the same amount of human IgG. We used trastuzumab as
the primary antibody because it recognizes the extracellular
domain of ErbB2. After washing the cells with PBS-A to re-
move unbound primary antibody, they were incubated with
goat anti-human IgG AlexaFluor488 (Invitrogen) at 4jC for
30 minutes. After further washing with PBS-A, the cells were
brought up in PBS-A, and flow cytometry was performed
using the Becton Dickinson FACScalibur apparatus (Becton
Dickinson, Palo Alto, CA). The percentage of cells with spe-
cific staining and the intensity of staining were determined
using the Becton Dickinson Cell Quest program.
Cell Cycle Analysis
Cells were plated onto 60-mm culture plates. The medium
was changed 48 hours later, and treatment was initiated as
described in figure legends. After 48 hours, cells were trypsi-
nized, washed thrice with ice-cold PBS, and resuspended in
propidium iodide solution. This solution contained 50 mg/ml
propidium iodide, 0.5% NP40, and 63 mg/ml RNase A in PBS.
After 30 minutes of incubation in the dark on ice, cell cycle
distribution was measured with a Becton Dickinson FACS-
calibur flow cytometer.
Results
EGF Prevents NE Differentiation in LNCaP Cells
To determine the effect of EGF on the NE differentiation of
LNCaP cells induced by long-term androgen deprivation,
LNCaP cells were serum-starved and treated with EGF
(108 M) for 5 days. Photomicrographs (Figure 1) illustrate
morphologic changes induced in response to these treat-
ments. Cells cultured without serum exhibited moderate mor-
phologic differentiation, as indicated by the appearance of
long and branched neuritic extensions that often possessed
growth cone–like structures. All these changes were asso-
ciated with the NE differentiation process. The formation of
neuritic processes was visible during the 2 to 3 days of
treatment and then continued to develop, persisting as long
as the cells were maintained under differentiating conditions.
However, the LNCaP cells treated with EGF in the absence
of serum exhibited a rounded morphology with short rarely
branched cellular processes, suggesting that EGF blocks the
acquisition of NE phenotype through induction by the ab-
sence of serum.
To evaluate NE differentiation more objectively, expres-
sion of NSE was examined by Western blot analysis. This
marker has previously been used to assess the extent of NE
differentiation in LNCaP cells [22,23]. As shown in Figure 1B,
in LNCaP cells grown in serum-free medium, NSE levels
Figure 1. Effect of EGF on cell morphology and NSE expression in LNCaP cells. LNCaP cells were cultured in RPMI with 7% FBS. After 2 days of culture, the
medium was removed, and the cells were washed with PBS, cultured in RPMI with 7% FBS (7%) or in the absence of serum (0%), and exposed to EGF (108 M)
for 4 days. (A) Phase-contrast photomicrographs illustrating morphologic changes in LNCaP cells were taken at 20 magnification 4 days after treatment. (B) NSE
expression in LNCaP cells after indicated treatment. ERK was used as an equal-loading marker. The figure is representative of four different experiments.
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were strongly elevated. The level of NSE was only slightly ele-
vated in EGF-treated cells.
These results indicate that EGF prevents the NE differ-
entiation of LNCaP cells induced by serum deprivation.
Effect of Gefitinib and Trastuzumab on EGFR/EGFR
Homodimers and EGFR/ErbB2 Heterodimers Induced By
EGF in LNCaP Cells
EGF binds to EGFR and promotes the formation of EGFR/
EGFR homodimers and EGFR/ErbB2 heterodimers. These
dimeric combinations of receptors are believed to produce
radically different downstream signals [20]. Because both
receptors have been detected in LNCaP cells, we sought to
determine which dimers are involved in the effect of EGF on
NE differentiation. To this end, we used gefitinib, an EGFR-
selective tyrosine kinase inhibitor, and trastuzumab, a mono-
clonal antibody that blocks ErbB2 function.
Firstly, we determined whether EGF induced the forma-
tion of EGFR/EGFR homodimers and EGFR/ErbB2 hetero-
dimers in LNCaP cells. As shown in Figure 2A, the addition
of EGF induced the phosphorylation of EGFR and ErbB2
in a time-dependent and dose-dependent manner. Maximal
phosphorylation was reached at the same time (5–10 min-
utes) of incubation and EGF concentration (108 M) for both
receptors. As ErbB2 does not have a known ligand, its phos-
phorylation could be due to transactivation, so EGFwould ac-
tivate EGFR, which in turnwould phosphorylate ErbB2 through
the EGFR/ErbB2 heterodimers formed. In fact, incubation of
LNCaP cells with gefitinib for 5, 15, and 30 minutes before
EGF stimulation markedly inhibited EGF-induced EGFR
phosphorylation without any accompanying change in EGFR
levels (Figure 2B, left). Gefitinib also inhibited EGF-induced
ErbB2 phosphorylation, which strongly suggests that ErbB2 is
transactivated by EGFR. Importantly, phosphorylation of ErbB2
was reduced in parallel with that of EGFR, illustrating the sig-
nificance of EGFR in maintaining the activity of ErbB2 and in
suggesting the existence of EGFR/ErbB2 heterodimers.
The pretreatment of LNCaP cells with trastuzumab 1, 3, 6,
and 24 hours before EGF stimulation decreased EGF-induced
ErbB2 phosphorylation (Figure 2B, right). This inhibition was
evident after 3 hours of treatment with trastuzumab and was
maximal after 24 hours. A decrease in ErbB2 levels with ki-
netics very similar to that of ErbB2 phosphorylation was also
observed, suggesting that the decrease in EGF-induced
ErbB2 phosphorylation could be due to downregulation of
ErbB2. However, trastuzumab did not modify the phosphory-
lation or the levels of EGFR, suggesting the existence of EGFR/
EGFR homodimers that maintain EGFR phosphorylation.
To confirm whether the downregulation of ERB2 levels
also reduced ErbB2 levels in the plasmamembrane, wemea-
sured the levels of ERB2 expression at the cell surface by
flow cytometry. As shown in Figure 2C, trastuzumab alone
or in combination with EGF reduced the surface expression
of ErbB2 by approximately 70%.
To provide direct additional evidence for EGFR/ErbB2
heterodimers and to confirm the results obtained with inhib-
itors, we incubated LNCaP cells with EGF alone or in com-
bination with gefitinib and trastuzumab, and then measured
the presence and the degree of phosphorylation of ErbB2
in EGFR immunoprecipitates. As shown in Figure 2D, ErbB2
coimmunoprecipitates with EGFR under basal conditions
and in the presence of EGF, although ErbB2 is phosphory-
lated only when LNCaP cells are treated with EGF. This
finding indicates that EGF activates previously constituted
EGFR/ErbB2 heterodimers. The presence of gefitinib slightly
increased the amount of ErbB2 that coimmunoprecipitated
with EGFR but completely inhibited its phosphorylation, sug-
gesting the presence of inactive heterodimers. Treatment
with trastuzumab reduced ErbB2 phosphorylation in parallel
with the formation of a smaller amount of heterodimers.
These findings strongly suggest that EGF induced the
activation EGFR/EGFR homodimers and EGFR/ErbB2 het-
erodimers. The activation of both types of dimer, but not
their formation, was inhibited by gefitinib, whereas tras-
tuzumab inhibited the activation and formation of EGFR/
ErbB2 heterodimers.
Effect of Gefitinib and Trastuzumab on Changes in LNCaP
Cell Morphology Induced By EGF
Having established the effect of gefitinib and trastuzumab
on EGFR and ErbB2 activation, we examined whether these
drugs modified the effect of EGF on LNCaP cell morphology.
Figure 3 illustrates that gefitinib, but not trastuzumab, pre-
vents the effect of EGF on LNCaP cell morphology. LNCaP
cells treated with EGF in the presence of gefitinib for 5 days
displayed a clear NE morphology (Figure 3A) coincident with
an increase in NSE expression (Figure 3B), indicating that
EGFR tyrosine kinase activity was required for EGF-induced
NE differentiation prevention. However, trastuzumab failed
to prevent the effect of EGF on LNCaP morphology and NSE
expression levels (Figure 3, A and B), which indicates that
ErbB2 may not be required.
Effect of LY294002 and U0126 on EGF-Dependent
Signaling in LNCaP Cells
To study the downstream effects of gefitinib and trastu-
zumab receptors, we analyzed the signaling pathway mole-
cules p42/44 MAPK and Akt, which are activated by ErbB
receptors in multiple biologic processes. The activation states
of the two enzymes were measured by immunoblotting with
antibodies specific for activating phosphorylation sites (see
the Materials and Methods section). As expected, MAPK
activity increased on treatment with EGF. The activation was
maximal after 5 to 10 minutes of EGF exposure and occurred
in a dose-dependent fashion (Figure 4A). When LNCaP cells
were pretreated with gefitinib, EGF-induced MAPK activation
was completely inhibited at all times tested (Figure 4B, left).
However, pretreatment with trastuzumab had no effect (Fig-
ure 4B, right), even after 24 hours, when the ErbB2 downreg-
ulation induced by trastuzumabwasmaximal (Figure 4B, right).
There were no significant differences in Akt activity with
the different treatments, possibly as a consequence of the
constitutively high basal levels of Akt activity observed (Fig-
ure 4, A and B). Signaling through the PI3K pathway is re-
quired to prevent cell death in LNCaP and also constitutive
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activation due to the loss of PTEN function previously de-
scribed in these cells [24].
These results suggest that EGF-induced NE differentia-
tion inhibition could be mediated by ERK1/2 activation and
requires Akt activity. To test this hypothesis, we incubated
LNCaP cells with EGF, EGF with U0126, or EGF with
LY294002, and examined the cell morphology and levels of
NSE. As shown in Figure 5, the presence of both inhibitors
Figure 2. Effect of gefitinib and trastuzumab on EGF-stimulated EGFR and ErbB2 activation in LNCaP cells. LNCaP cells were cultured in RPMI with 7% FBS for
2 days and then placed in serum-free medium for 24 hours. (A) The cells were then treated for 5 minutes with increasing concentrations of EGF (left) with 108 M
EGF for the indicated times (right), or (B) were pretreated with 5 M gefitinib (left) or 25 g/ml trastuzumab (right) for the indicated times before adding 108 M EGF
for 5 minutes. Cellular lysates were monitored by immunoblotting using specific antibodies against the phosphorylated and total forms of EGFR and ErbB2, as
described in the Materials and Methods section. (C) Effect of trastuzumab on cell surface ErbB2. Serum-starved cells were treated with 25 g/ml trastuzumab
alone or in combination with 108 M EGF for 24 hours. ErbB2 levels were determined by FACScan analysis with specific anti-ErbB2 antibody, as described in the
Materials and Methods section. The nonspecific area corresponds to staining arising from the omission of the primary antibody. Ordinate: relative cell number;
abscissa: log fluorescence. (D) Effect of gefitinib and trastuzumab on EGFR/ErbB2 heterodimer formation induced by EGF. Serum-starved cells were pretreated
with 5 M gefitinib for 30 minutes or with 25 g/ml trastuzumab for 24 hours before adding 108 M EGF for 5 minutes. Protein lysates were quantified, and equal
amounts of total protein were then subjected to immunoprecipitation using anti-EGFR antibody. Immunoprecipitates were monitored by Western blot analysis using
specific antibodies against the phosphorylated and total forms of ErbB2, as described in the Materials and Methods section. The total EGFR level was used as an
equal-loading marker. Each figure is representative of four different experiments.
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Figure 3. Effect of gefitinib and trastuzumab in the presence of EGF on LNCaP cell morphology. LNCaP cells were cultured in RPMI with 7% FBS. After 2 days of
culture, the medium was removed, and the cells were washed with PBS, cultured in RPMI in the absence of serum, and exposed to EGF (108 M), alone or in
combination with gefitinib (5 M) or trastuzumab (25 g/ml), for 4 days. (A) Phase-contrast photomicrographs illustrating morphologic changes in LNCaP cells were
taken at 20 magnification 4 days after treatment. (B) NSE expression in LNCaP cells after indicated treatment. ERK was used as an equal-loading marker. The
figure is representative of six different experiments.
Figure 4. Effect of gefitinib and trastuzumab on EGF-stimulated signaling pathways. LNCaP cells were cultured in RPMI with 7% FBS for 2 days and then placed in
serum-free medium for 24 hours. (A) The cells were then treated for 5 minutes with increasing concentrations of EGF (left) or with 108 M EGF for the indicated
times (right). (B) Serum-starved cells were pretreated with gefitinib (5 M; left) or trastuzumab (25 g/ml; right) for the indicated times before adding 108 M EGF
for 5 minutes. Cellular lysates were monitored by immunoblotting using the indicated specific antibodies, as described in the Materials and Methods section. The
figure is representative of three different experiments.
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prevented EGF effects and induced NE differentiation, as
demonstrated by changes in cell morphology. NSE levels also
increased, suggesting that EGF-induced NE differentiation in-
hibition requires ERK1/2 and Akt activity.
Effect of Gefitinib, Trastuzumab, U0126, and LY294002
on the Presence of EGF in Cell Cycle Progression
Although one characteristic ascribed to prostatic NE cells
is loss of mitogenic activity, it has also been suggested that
NE differentiation is not obligatorily coupled to withdrawal
from the cell cycle [22]. To determine whether acquisition or
loss of the NE phenotype detected with our treatments is
associated with changes in mitotic activity, we analyzed the
effect of these treatments on cell cycle progression. As
shown in Figure 6, stimulation of quiescent LNCaP cells with
EGF led to a 65% increase in S-phase fraction. The pres-
ence of 5 mM gefitinib, 5 mM U0126, or 20 mM LY294002
prevented the effect of EGF decreasing the percentage of
cells in S-phase by 70%, 60%, and 80% respectively, com-
pared with EGF alone. Moreover, gefitinib and LY294002
also decreased the number of cells in G2/M-phase by about
50%. Finally, treatment with trastuzumab did not alter the
cell cycle distribution of LNCaP cells incubated with EGF.
These results clearly demonstrate that these treatment-
inducing morphologic changes also block cell cycle progres-
sion, showing a direct association between NE differentiation
and inhibition of the mitotic activity of LNCaP cells.
Discussion
Cells with NE phenotype increase in number as cancer prog-
resses to an androgen-refractory condition, and they be-
come the prevalent cell type after long-term antiandrogen
therapy [7]. In this study, we have demonstrated that EGF, a
growth factor implicated in prostatic tumoral progression, pre-
vents NE differentiation induced by hormonal deprivation.
We have used the androgen-responsive prostate tumor
cell line LNCaP, which acquires an NE phenotype in response
Figure 5. Effect of LY294002 and U0126 in the presence of EGF on LNCaP cell morphology. LNCaP cells were cultured in RPMI with 7% FBS; after 2 days of
culture, the medium was removed, and the cells were washed with PBS, cultured in serum-free medium, and exposed to EGF (108 M), alone or in combination
with LY294002 (20 M) or U0126 (5 M), for 4 days. (A) Phase-contrast photomicrographs illustrating morphologic changes in LNCaP cells were taken at 20
magnification 4 days after treatment. (B) NSE expression in LNCaP cells after indicated treatment. Actin was used as an equal-loading marker. The figure is
representative of six different experiments.
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to certain culture manipulations, including prolonged andro-
gen depletion [25], pharmacological elevation of intracellular
cAMP [26,27], and exposure of cells to heparin-binding EGF-
like growth factor [22] or interleukin-6 [23]. In our case, we
chose the transdifferentiation of LNCaP induced by androgen
depletion resembling the clinical phenomenon in androgen
ablation therapy. This transdifferentiation is characterized by
the appearance of long, branched, neurite-like processes; in-
hibition of mitotic activity; and increased expression of NE
markers such as NSE. EGF prevented all these changes:
Cells exhibited fewer and shorter processes, lower NSE lev-
els, and renewed mitotic activity, suggesting that cells did not
acquire an NE phenotype.
We have demonstrated that in LNCaP cells, EGF acti-
vates EGFR and ErbB2 through the formation of EGFR/
ErbB2 dimers. This finding is supported by several pieces
of evidence. First, ErbB2, a receptor with no known ligand,
was phosphorylated by EGF in parallel with EGFR. Second,
the inhibition of EGFR tyrosine kinase by gefitinib blocked
100% EGF-stimulated ErbB2 phosphorylation in parallel
with that EGFR. Gefitinib also targets the tyrosine kinase
domain of ErbB2, although because the IC50 (>3.7 mM) of
gefitinib for the inhibition of ErbB2 kinase activity in vitro
is at least two orders of magnitude greater that that for the
inhibition of EGFR (0.033 mM) [28], it is unlikely that such
a mechanism is responsible in this instance. Third, ErbB2
coimmunoprecipitates with EGFR and is activated in the
presence of EGF.
Furthermore, we analyzed the specific contributions of
both receptors to EGF-mediated NE differentiation inhibition,
demonstrating that the presence of ErbB2 is not necessary.
Gefitinib was not a useful inhibitor for discriminating between
the two receptors because it inhibits the activation of EGFR
and ErbB2. However, trastuzumab drastically reduced ErbB2
levels and EGFR/ErbB2 heterodimer formation, but it did not
inhibit either EGFR phosphorylation or EGF-dependent sig-
naling, which suggests that EGFR activation was sufficient to
prevent NE differentiation and that the absence of ErbB2 can
be compensated by EGFR. In fact, the reduction of EGFR/
ErB2 heterodimer formation by the use of trastuzumab could
promote the liberation of EGFR and EGFR/EGFR homodime-
rization. These homodimers could activate ERK1/2 and cell
proliferation, mediating the inhibition of NE differentiation by
EGF in the absence of ErbB2. These results are surprising
given the demonstration by Mellinghoff et al. [29] that ErbB2,
but not EGFR, is required to impair growth and androgen
Figure 6. Gefitinib, U0126, and LY294002, but not trastuzumab, in the presence of EGF induces G1 arrest in LNCaP cells. LNCaP cells were cultured in RPMI with
7% FBS; after 2 days of culture, the medium was removed, and the cells were washed with PBS, cultured in RPMI in the absence of serum (0%), and exposed to
EGF (108 M), alone or in combination with gefitinib (5 M), trastuzumab, (25 g/ml), U0126 (5 M), or LY294002 (20 M), for 2 days. After the desired treatment,
cells were trypsinized, and FACS analysis was performed as described in the Materials and Methods section. The cell cycle phase distribution is representative of
four different experiments with similar findings. Numeric data are presented as the mean ± SEM of these four experiments.
EGF Prevents Prostatic Neuroendocrine Differentiation Martı´n-Orozco et al. 621
Neoplasia . Vol. 9, No. 8, 2007
receptor activity in human prostate cancer cell lines. More-
over, forced overexpression of ErbB2 in prostate cancer
cells enhances androgen receptor function and hormone-
independent growth [30,31]. It is possible that the relative
contribution of EGFR and ErbB2 to tumoral progression was
dependent on the particular repertoire of ErbB receptors and
their relative expression levels on different stages of the tumor.
It is interesting to note that we have detected in LNCaP
cells EGFR/ErbB2 heterodimers previously constituted in
basal conditions that are activated by the addition of EGF.
EGF produced by LNCaP cells [32] may be responsible for
the formation of the hetorodimers detected. However, the ab-
sence of the phosphorylation of EGFR and ErbB2 in basal
conditions rules out this possibility. Other authors have also
demonstrated the presence of EGFR dimers in the absence
of EGF stimulation, which indicates that receptor dimeriza-
tion and activation are mechanistically distinct and separable
events [33,34].
Our data suggest that ERK1/2 is involved in the EGF-
mediated inhibition of NE differentiation. In fact, ERKs were
activated under culture conditions in which NE differentia-
tion was not observed, and the MEK inhibitor U0126 blocked
the effect of the EGF induction of NE differentiation and in-
creased NSE levels. Interestingly, Akt activity was not mod-
ified by any of the treatments, but its inhibition blocked the
effect of EGF on NE differentiation. The PI3K/Akt pathway is
constitutively active in LNCaP cells due to a mutation in the
PTEN tumor-suppressor gene, a negative regulator of this
pathway [35]. The importance of this pathway for cell survival
in the absence of androgens is obvious because treatment
with the PI3K inhibitor LY294002 leads to apoptosis. This
apoptotic effect can be antagonized by different ligands of
EGFR, including EGF [24]. Consistent with these data,
we found that EGF rescued LNCaP cells from LY294002-
induced apoptosis but was unable to stimulate cell prolifer-
ation or to inhibit NE differentiation. These findings suggest
that abrogation of PI3K/Akt signaling changed the prolif-
erative role of EGF in LNCaP cells to one of differentiation.
The clinical relevance of our findings is indicated by a recent
clinicopathological study showing that phosphorylation of
Akt is an excellent predictor of poor clinical outcome in pros-
tate cancer [36]; this raises the possibility that targeting the
PI3K pathway may prove to be an effective means of che-
motherapeutic intervention in vivo. However, the ability of
the PI3K/Akt pathway to modulate the effect of EGF must
be taken into account. Inhibitors of PI3K/Akt could induce
apoptosis and tumor regression, but their effect could be
compensated by the presence of EGF stimulating an alter-
native survival signal. Under these conditions, EGF will not
directly stimulate cell proliferation but could increase the num-
ber of mitogenic factor–secretor NE cells contributing to tu-
moral progression.
Results obtained with gefitinib and trastuzumab have
been useful not only for characterizing the receptors and in-
tracellular pathways that drive NE differentiation inhibition
by EGF but also for examining the mechanisms of action of
these inhibitors. In this study, we have shown that gefitinib
strongly inhibits EGF-dependent signaling through a double
complementary mechanism of action: the inhibition of EGFR
and ErbB2 activation, and the formation of inactive EGFR/
ErbB2 heterodimers. The formation of inactive EGFR/ErbB2
heterodimers could potentially reduce the population of
ErbB2 available to form new secondary dimers with other
ErbB receptors present in LNCaP cells [37,38]. This dou-
ble mechanism may explain the very efficient prevention by
gefitinib of EGF-dependent signaling in LNCaP cells. These
findings substantiate and extend a number of reports that
demonstrate the antiproliferative effects of gefitinib on other
prostatic cancer cell lines and on human prostate cancer
xenografts, and support the use of gefitinib in the treatment
of prostate cancer. Unfortunately, the activity of gefitinib in
recent prostate cancer trials has been disappointing [39].
We may speculate on whether the capacity of gefitinib to
induce NE differentiation in the presence of EGF was the
principal reason for the failure of gefitinib. This inhibitor may
be able to suppress cell proliferation stimulated by EGF but
in turn induces NE differentiation that could provide prolifera-
tive stimuli to surrounding cancer cells.
Trastuzumab, a humanized monoclonal antibody, is an ef-
fective treatment for advanced breast cancer with ErbB2
gene amplification but has a poor efficacy in treating hormone-
refractory prostate cancer. Although it is not clear how trastu-
zumab works, stimulation of ErbB2 endocytosis and removal of
ErbB2 from the cell surface in overexpressing cells seem to
be principal elements of its effectiveness [40]. In this context,
our studies have shown that trastuzumab reduced ErbB2
levels and the formation of active EGFR/ErbB2 heterodimers
in LNCaP cells that did not overexpress ErbB2 but did not
inhibit EGF effects. Thus, the downregulation of ErbB2 in-
duced by trastuzumab was not always associated with its
efficacy [41,42]. In our case, the inefficacy of trastuzumab in
inhibiting the effect of EGF seems be due to the coexpres-
sion of EGFR, which circumvents the absence of ErbB2
produced by trastuzumab. This suggests that the biologic
function of ErbB2 in each case and the relative levels of
the other ErbB receptors may be more important than the
expression level of ErbB2. Another possible explanation for
the inefficacy of trastuzumab is the absence of PTEN from
LNCaP cells. Nagata et al. [41] have demonstrated that
trastuzumab responsiveness depends not only on the down-
regulation of ErbB2 and the inhibition of ErbB2-related down-
stream events but also on the status of PTEN. They report
that trastuzumab specifically downregulates PI3K signaling
through activation of PTEN and that PTEN loss renders
ErbB2-overexpressing breast cancer resistant to trastuzumab-
based therapy. Therefore, it is pertinent to investigate in LNCaP
cells whether the efficacy of trastuzumab could be enhanced
with inhibitors of the PI3K pathway. It might be worthwhile to
reconsider trastuzumab-based chemotherapy for prostate
cancer if the principal reason for the failure of trastuzumab
has been inadequate PI3K inhibition because this could be
overcome by the addition of a PI3K pathway inhibitor.
In summary, we have demonstrated that, in LNCaP cells,
EGF prevents the acquisition of NE phenotype by an ErbB2-
independent and ERK1/2–dependent mechanism and
requires Akt activation. We have also shown that EGFR
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tyrosine kinase and PI3K inhibitors can inhibit the cell pro-
liferation stimulated by EGF but induce the acquisition of NE
phenotype. Under these conditions, EGF does not directly
stimulate cell proliferation but could increase the population
of mitogenic factor–secretor NE cells that maintain the
growth potential of tumor cells. Such that EGFR, HER-2, and
Akt constitute biologic targets for innovative treatment in
hormone-refractory prostate cancer [43,44], the present data
should be borne in mind when designing new clinical sched-
ules for the treatment of prostate cancer, including the use of
ErbB receptors and associated signaling pathway inhibitors.
References
[1] Huggins C (1967). Endocrine-induced regression of cancers. Cancer
Res 27, 1925–1930.
[2] Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J,
Reiter RE, and Sawyers CL (1999). Evidence for clonal outgrowth of
androgen-independent prostate cancer cells from androgen-dependent
tumors through a two-step process. Cancer Res 59, 5030–5036.
[3] Evangelou AI, Winter SF, Huss WJ, Bok RA, and Greenberg NM (2004).
Steroid hormones, polypeptide growth factors, hormone refractory pros-
tate cancer, and the neuroendocrine phenotype. J Cell Biochem 91,
671–683.
[4] Abrahamsson A (1999). Neuroendocrine differentiation in prostatic car-
cinoma. Prostate 39, 135–148.
[5] Bonkhoff H (2001). Neuroendocrine differentiation in human prostate
cancer. Morphogenesis, proliferation and androgen receptor status.
Ann Oncol 12 (Suppl 2), S141–S144.
[6] Guate JL, Escaf S, Menendez CL, del Valle M, and Vega JA (1997).
Neuroendocrine cells in benign prostatic hyperplasia and prostatic car-
cinoma: effect of hormonal treatment. Urol Int 59, 149–153.
[7] Hirano D, Okada Y, Minei S, Takimoto Y, and Nemoto N (2004). Neuro-
endocrine differentiation in hormone refractory prostate cancer following
androgen deprivation therapy. Eur Urol 45, 586–592.
[8] Cussenot O, Villette JM, Cochand-Priollet B, and Berthon P (1998).
Evaluation and clinical value of neuroendocrine differentiation in human
prostatic tumors. Prostate Suppl 8, 43–51.
[9] Fixemer T, Remberger K, and Bonkhoff H (2002). Apoptosis resistance
of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate
53, 118–123.
[10] Grobholz R, Griebe M, Sauer CG, Michel MS, Trojan L, and Bleyl U
(2005). Influence of neuroendocrine tumor cells on proliferation in pros-
tatic carcinoma. Hum Pathol 36, 562–570.
[11] Vashchenko N and Abrahamsson PA (2005). Neuroendocrine differen-
tiation in prostate cancer: implications for new treatment modalities. Eur
Urol 47, 147–155.
[12] Bonkhoff H, Wernert N, Dhom G, and Remberger K (1991). Relation of
endocrine–paracrine cells to cell proliferation in normal, hyperplastic,
and neoplastic human prostate. Prostate 19, 91–98.
[13] Cockett AT, di Sant’Agnese PA, Gopinath P, Schoen SR, and Abra-
hamsson PA (1993). Relationship of neuroendocrine cells of prostate
and serotonin to benign prostatic hyperplasia. Urology 42, 512–519.
[14] Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ,
Slezak JM, and Cheng L (2002). Neuroendocrine expression in node
positive prostate cancer: correlation with systemic progression and pa-
tient survival. J Urol 168, 1204–1211.
[15] El Sheikh SS, Domin J, Abel P, Stamp G, and Lalani el-N (2004).
Phosphorylation of both EGFR and ErbB2 is a reliable predictor of
prostate cancer cell proliferation in response to EGF. Neoplasia 6,
846–853.
[16] Ratan HL, Gescher A, Steward WP, and Mellon JK (2003). ErbB re-
ceptors: possible therapeutic targets in prostate cancer? BJU Int 92,
890–895.
[17] Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P,
Fuks Z, Mendelsohn J, and Cordon-Cardo C (1995). Changing pattern
of expression of the epidermal growth factor receptor and transforming
growth factor alpha in the progression of prostatic neoplasms. Clin
Cancer Res 1, 545–550.
[18] Olayioye MA, Neve RM, Lane HA, and Hynes NE (2000). The ErbB
signaling network: receptor heterodimerization in development and can-
cer. EMBO J 19, 159–167.
[19] Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A,
Bartsch G, and Klocker H (1994). Androgen receptor activation in pros-
tatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth
factor, and epidermal growth factor. Cancer Res 54, 5474–5478.
[20] Yarden Y and Sliwkowski MX (2001). Untangling the ErbB signalling
network. Nat Rev Mol Cell Biol 2, 127–137.
[21] Hynes NE and Lane HA (2005). ERBB receptors and cancer: the com-
plexity of targeted inhibitors. Nat Rev Cancer 5, 341–354.
[22] Kim J, Adam RM, and Freeman MR (2002). Activation of the ERK
mitogen-activated protein kinase pathway stimulates neuroendocrine
differentiation in LNCaP cells independently of cell cycle withdrawal
and STAT3 phosphorylation. Cancer Res 62, 1549–1554.
[23] Deeble PD, Murphy DJ, Parsons SJ, and Cox ME (2001). Interleukin-6–
and cyclic AMP–mediated signaling potentiates neuroendocrine differ-
entiation of LNCaP prostate tumor cells. Mol Cell Biol 21, 8471–8482.
[24] Lin J, Adam RM, Santiestevan E, and Freeman MR (1999). The phos-
phatidylinositol 3V-kinase pathway is a dominant growth factor – acti-
vated cell survival pathway in LNCaP human prostate carcinoma cells.
Cancer Res 59, 2891–2897.
[25] Shen R, Dorai T, Szaboles M, Katz AE, Olsson CA, and Buttyan R (1997).
Transdifferentiation of cultured human prostate cells to a neuroendocrine
cell phenotype in a hormone-depleted medium. Urol Res 3, 67–75.
[26] Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ,
Tsokos M, Sheahan MD, and Nguyen P (1994). Terminal neuroendocrine
differentiation of human prostate carcinoma cells in response to increased
intracellular cyclic AMP. Proc Natl Acad Sci USA 91, 5330–5334.
[27] Cox ME, Deeble PD, Lakhani S, and Parsons SJ (1999). Acquisition of
neuroendocrine characteristics by prostate tumor cells is reversible: impli-
cations for prostate cancer progression. Cancer Res 59, 3821–3830.
[28] Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, and
Arteaga CL (2001). Epidermal growth factor receptor (HER1) tyrosine
kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)–overexpress-
ing breast cancer cells in vitro and in vivo. Cancer Res 61, 8887–8895.
[29] Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, and Sawyers
CL (2004). HER2/neu kinase–dependent modulation of androgen re-
ceptor function through effects on DNA binding and stability. Cancer
Cell 6, 517–527.
[30] Craft N, Shostak Y, Carey M, and Sawyers CL (1999). A mechanism for
hormone-independent prostate cancer through modulation of androgen
receptor signalling by HER2-neu tyrosine kinase. Nat Med 5, 280–285.
[31] Ye S, Lin HK, Kang HY, Thin TH, Lin MF, and Chang C (1999). From
HER2/neu signal cascade to androgen receptor and its coactivators: a
novel pathway by induction of androgen target genes through MAP ki-
nase in prostate cancer cells. Proc Natl Acad Sci USA 96, 5458–5463.
[32] Limonta P, Dondi D, Marelli MM, Moretti RM, Negri-Cesi P, and Motta M
(1995). Growth of the androgen-dependent tumor of the prostate: role of
androgens and of locally expressed growth modulatory factors. J Ste-
roid Biochem Mol Biol 53, 401–405.
[33] Johannessen LE, Haugen KE, Østvold AC, Stang E, and Madshus IH
(2001). Heterodimerization of the epidermal-growth-factor (EGF) recep-
tor and ErbB2 and the affinity of EGF binding are regulated by different
mechanisms. Biochem J 35, 87–96.
[34] Yu X, Sharma KD, Takahashi T, Iwamoto R, and Mekada E (2002).
Ligand-independent dimer formation of epidermal growth factor recep-
tor (EGFR) is a step separable from ligand-induced EGFR signalling.
Mol Biol Cell 13, 2547–2557.
[35] Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, and
Trapma NJ (1998). Frequent inactivation of PTEN in prostate cancer
cell lines and xenografts. Cancer Res 58, 2720–2723.
[36] Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg
PM, and Ghosh PM (2004). Phosphorylation of Akt (Ser473) is an ex-
cellent predictor of poor clinical outcome in prostate cancer. Cancer Res
64, 5232–5236.
[37] Gamett DC, Pearson G, Cerione RA, and Friedberg I (1997). Sec-
ondary dimerization between members of the epidermal growth factor
receptor family. J Biol Chem 272, 12052–12056.
[38] Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J, Averbuch S,
and Baselga J (2003). ZD1839, a specific epidermal growth factor re-
ceptor (EGFR) tyrosine kinase inhibitor, induces the formation of inac-
tive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin
signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9,
1274–1283.
[39] Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S,
Ernst DS, Douglas L, Brundage M, et al. (2005). Randomized phase II
study of two doses of gefitinib in hormone-refractory prostate cancer: a
trial of the National Cancer Institute of Canada—Clinical Trials Group. J
Clin Oncol 23, 455–460.
EGF Prevents Prostatic Neuroendocrine Differentiation Martı´n-Orozco et al. 623
Neoplasia . Vol. 9, No. 8, 2007
[40] Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, and
Fox JA (1999). Nonclinical studies addressing the mechanism
of action of trastuzumab (Herceptin). Semin Oncol 26 (Suppl 12),
60–70.
[41] Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P,
Monia BP, Nguyen NT, et al. (2004). PTEN activation contributes to
tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab
resistance in patients. Cancer Cell 6, 117–127.
[42] Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG,
Jen J, Isaacs WB, Bova GS, and Sidransky D (1997). Frequent inacti-
vation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57,
4997–5000.
[43] Baselga J, Rischin D, Ranson M, Calvert H, Raymond E, Kieback DG,
Kaye SB, Gianni L, Harris A, Bjork T, et al. (2002). Phase I safety, phar-
macokinetic, and pharmacodynamic trial of ZD1839, a selective oral epi-
dermal growth factor receptor tyrosine kinase inhibitor, in patients with
five selected solid tumours types. J Clin Oncol 20, 4292–4302.
[44] Small EJ, Bok R, Reese DM, Sudilovsky D, and Frohlich M (2001).
Docetaxel, estramustine, plus trastuzumab in patients with metastatic
androgen-independent prostate cancer. Semin Oncol 28, 71–76.
624 EGF Prevents Prostatic Neuroendocrine Differentiation Martı´n-Orozco et al.
Neoplasia . Vol. 9, No. 8, 2007
